Novavax shares exploded higher during the regular session, significantly outperforming the broader biotechnology sector. The primary catalyst was the announcement that Sanofi is actively carrying the Nuvaxovid COVID-19 shot into the current fall vaccination season. While peers like Moderna also saw gains, the market rewarded Novavax with substantially more intensity as the company's partnership with Sanofi moved into its operational phase.